Cargando…

Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients

Polymyxin B (PMB) has reemerged as a last‐line therapy for infections caused by multidrug‐resistant gram‐negative pathogens, but dosing is challenging because of its narrow therapeutic window and pharmacokinetic (PK) variability. Population PK (POPPK) models based on suitably powered clinical studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanafin, Patrick O., Nation, Roger L., Scheetz, Marc H., Zavascki, Alexandre P., Sandri, Ana M., Kwa, Andrea L., Cherng, Benjamin P. Z., Kubin, Christine J., Yin, Michael T., Wang, Jiping, Li, Jian, Kaye, Keith S., Rao, Gauri G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674003/ https://www.ncbi.nlm.nih.gov/pubmed/34811968 http://dx.doi.org/10.1002/psp4.12720

Ejemplares similares

Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
por: Nation, Roger L., et al.
Publicado: (2019)

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis()
por: Abboud, Cely Saad, et al.
Publicado: (2017)

Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures
por: Tam, Vincent H., et al.
Publicado: (2020)

A Review of the Clinical Pharmacokinetics of Polymyxin B
por: Avedissian, Sean N., et al.
Publicado: (2019)

Teaching ‘Old’ Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative ‘Superbugs’
por: Velkov, Tony, et al.
Publicado: (2014)

Shifting Gears: The Future of Polymyxin Antibiotics
por: Lenhard, Justin R., et al.
Publicado: (2019)

Design and Evaluation of Novel Polymyxin Fluorescent Probes
por: Yun, Bo, et al.
Publicado: (2017)

Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae
por: Hanafin, Patrick O., et al.
Publicado: (2023)

Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
por: Liang, Danhong, et al.
Publicado: (2023)

Population pharmacokinetics of polymyxin B: a systematic review
por: Chen, Na, et al.
Publicado: (2022)

Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates
por: Barin, Juliana, et al.
Publicado: (2013)

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
por: Bergen, Phillip J., et al.
Publicado: (2015)

In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii
por: Netto, Bárbara, et al.
Publicado: (2013)

Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing
por: Jermain, Brian, et al.
Publicado: (2020)

A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B
por: Krzyzanski, Wojciech, et al.
Publicado: (2017)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa
por: Lin, Yu-Wei, et al.
Publicado: (2019)

Transcriptomic Analysis of the Activity of a Novel Polymyxin against Staphylococcus aureus
por: Zhao, Jinxin, et al.
Publicado: (2016)

Probing the Penetration of Antimicrobial Polymyxin Lipopeptides into Gram-Negative Bacteria
por: Deris, Zakuan Z., et al.
Publicado: (2014)

1266. Melatonin for Renal Protection of Patients Treated with Polymyxin B: A Double Blind Randomized Clinical Trial
por: Rigatto, Maria Helena, et al.
Publicado: (2021)

2815. Outcomes of Novel Antimicrobials Compared to Polymyxin B for treatment of infections due Carbapenem-Resistant Enterobacterales Infections
por: Zheng, Tina, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Efficacy and pharmacokinetics of intravenous paracetamol in the critically ill patient
por: Samson, AD, et al.
Publicado: (2009)

Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model
por: Garcia, Estefany, et al.
Publicado: (2021)

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens
por: Tran, Thien B., et al.
Publicado: (2018)

Efficacy and safety of intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of multidrug-resistant gram-negative bacterial pneumonia: A systematic review and meta-analysis
por: Lu, Difan, et al.
Publicado: (2023)

707. QPX9003: Pharmacology of a Novel Polymyxin in Mice and Rats
por: Sabet, Mojgan, et al.
Publicado: (2019)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil
por: Bartolleti, Flávia, et al.
Publicado: (2016)

Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii
por: Mahamad Maifiah, Mohd Hafidz, et al.
Publicado: (2016)

Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens
por: Cheah, Soon-Ee, et al.
Publicado: (2016)

Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children
por: Hartman, Stan J. F., et al.
Publicado: (2022)

A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity
por: Deris, Zakuan Z., et al.
Publicado: (2013)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
por: Luterbach, Courtney L., et al.
Publicado: (2022)

Epidemiology of Polymyxin Use in a Tertiary Care Setting of South India
por: Menon, Vidya, et al.
Publicado: (2017)

Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study
por: Siddiqui, Naveed-ur-Rehman, et al.
Publicado: (2014)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia
por: Zeng, Huihui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_06k7l3oc6ig3fhg6l53r9r8td0